August 20, 2024

SARC 044 Open for Enrollment
SARC’s newest clinical trial, SARC044, is now open for enrollment! This trial aims to enroll patients with GIST who have previously progressed on sunitinib.
Read moreAs we continue to build this new database, we invite all sarcoma centers to apply and register.
The Sarcoma Centers Registry is a directory of sarcoma institutions, centers, and practices worldwide. Centers can be filtered by pediatric and adult care, and each center has a summary page with self-reported, detailed information, including useful contact information and a Google map link.
All centers included in the Registry have voluntarily submitted data that meets specific, objective criteria. These centers are united in their commitment to advancing sarcoma research through collaboration. Centers indicated as SARC Consortium Members have additionally executed a master collaboration research agreement with SARC. About consortium members.
SARC’s newest clinical trial, SARC044, is now open for enrollment! This trial aims to enroll patients with GIST who have previously progressed on sunitinib.
Read moreDr. Patrick Grohar presented the SARC037 findings at ASCO 2024. The results suggest that EWS::FLI1 is a target for Ewing sarcoma and the combination of trabectedin/irinotecan is active in treatment-refractory Ewing sarcoma patients.
Read moreIn this SARC Sarcoma Centers Spotlight we feature Jessica Lowenstein, M.S., DABR, a medical physicist, and Hannah Nguyen, M.S. (RS), CMD, a medical dosimetrist, both of whom work at RQA Lab and IROC Houston located at MD Anderson Cancer Center.
Read moreDr. David Kirsch unveiled the SU2C-SARC032 findings at ASCO 2024. The results indicate that adding pembro decreases the risk of cancer recurrence by 43% two years after treatment.
Read moreSARC, alongside sarcoma research leaders like Cogent Biosciences, Dana Farber Cancer Institute and The Life Raft Group, is committed to collaborating to advance treatment options for GIST patients.
Read moreSARC032 and SARC037 to be presented at ASCO 2024.
Read moreIn a rare disease as Ewing sarcoma, we recognize we need to work together to complete important studies like this.
Read moreDerek Fadness was only the second patient in the nation to join this clinical trial. Read his remarkable story.
Read moreSU2C has made additional funds available for SARC032 so that we can increase the sample size and power of this randomized, ongoing trial from 102 to 126 evaluable patients. SARC032 …
Read moreTogether we give. Giving Tuesday is on Tuesday, November 30. It is a designated day each year to encourage charitable giving to support those who need our help. By donating, …
Read moreNotifications